<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747328</url>
  </required_header>
  <id_info>
    <org_study_id>LS007</org_study_id>
    <nct_id>NCT03747328</nct_id>
  </id_info>
  <brief_title>ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome</brief_title>
  <official_title>A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Clinical Activity of ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aadi, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aadi, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2a, open-label study to evaluate the safety, tolerability, and clinical activity of
      ABI-009 (nab-sirolimus) in patients with genetically-confirmed Leigh or Leigh-like syndrome
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor Function Measure (GMFM)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The GMFM is a standardized observational instrument designed and validated to measure change in gross motor function over time in children</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Leigh Syndrome</condition>
  <arm_group>
    <arm_group_label>ABI-009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009</intervention_name>
    <description>nanoparticle albumin bound sirolimus</description>
    <arm_group_label>ABI-009</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient will be eligible for inclusion in this study only if all of the following
        criteria are met at screening:

          1. Diagnosis of genetically-confirmed Leigh or Leigh-like syndrome, as well as documented
             clinical evidence (including demonstrated neurologic manifestations) of the syndrome,
             as confirmed by the investigator.

          2. Moderate disease severity based on NPMDS score of &gt;15 on Sections I through III,
             inclusive.

          3. Male or female patients, ≥2 and ≤17 years of age at the time of enrollment.

          4. Body weight ≥5 kg (11 lbs) at the time of enrollment.

          5. Chronic, stable disease, as determined by the investigator, for a minimum of 3 months
             prior to enrollment. This includes, but is not limited to, patients without
             hospitalizations or emergency room visits, or fever &lt;101 F, and/or acute illness.

          6. Adequate liver function:

               1. Total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dL

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;3 x ULN.

          7. Adequate renal function as defined by serum creatinine &lt;ULN for each individual
             patient's age category.

          8. Adequate biological parameters:

               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L

               2. Platelet count ≥100,000/mm3 (100 × 109/L)

               3. Hemoglobin ≥9 g/dL.

               4. Adequate immunoglobulin levels (IgG, IgA, IgM) that, in the opinion of the
                  investigator, will not place the patient at increased risk for infection.

               5. Serum amylase and lipase &lt;2 x ULN.

               6. Non-fasting serum triglyceride ≤300 mg/dL and non-fasting serum cholesterol ≤300
                  mg/dL, collected within 1 to 4 hours following a meal.

          9. If receiving prescribed medication to prevent or treat seizures, the patient must be
             receiving stable doses for at least 1 month prior to screening visit.

         10. Sexually active males with female partners of child-bearing potential or non-pregnant
             and non-breast feeding female of child-bearing potential:

               -  Females of child-bearing potential must agree to use effective contraception
                  without interruption from 28 days prior to starting IP throughout 3 months after
                  last dose of IP and have a negative urine pregnancy test (β-hCG) result at
                  screening and agree to ongoing pregnancy testing during the course of the study,
                  and after the end of study treatment. A second form of birth control is required
                  even if the patient has had a tubal ligation.

               -  Male patients must practice abstinence or agree to use a condom during sexual
                  contact with a pregnant female or a female of childbearing potential while
                  participating in the study and throughout 3 months after the last dose of IP. A
                  second form of birth control is required even if the patient has undergone a
                  successful vasectomy.

         11. The patient (when applicable) or the patient's parent(s) or legal guardian(s)
             understand(s) and voluntarily signed the informed consent document(s) prior to any
             study-related assessments/procedures being conducted.

         12. The patient or parent(s)/guardian(s) is/are willing and able to comply with the study
             visit schedule and other protocol requirements, in the opinion of the investigator.

        Exclusion Criteria:

        A patient will not be eligible for inclusion in this study if any of the following criteria
        apply at screening:

          1. Renal insufficiency that, in the opinion of the investigator, requires or may require
             dialysis during the treatment and follow-up periods.

          2. Cardiac ejection fraction/shortening fraction ≤50 % and/or severe end-organ
             hypo-perfusion syndrome (secondary to cardiac failure) resulting in lactic acidosis.

          3. Patients with implanted cardiac assist/medical devices (including pacemakers), unless
             device was implanted prophylactically, and the patient is clinically asymptomatic.

          4. In the opinion of the investigator, clinically significant ECG and/or ECHO findings at
             the time of screening.

          5. Myocardial infarction within 6 months prior to enrollment.

          6. Symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac
             arrhythmia, uncontrolled hypertension, or unstable coronary artery disease.

          7. Prior exposure to ABI-009, sirolimus, everolimus, or any other known rapamycin
             derivative/rapalog, or previous treatment with any known mTOR inhibitor.

          8. Patients who are breast feeding or have a confirmed or suspected pregnancy.

          9. Treatment with any investigational drug (ie, a drug for which there is no approved
             indication), including an investigational drug for mitochondrial disease within 1
             month prior to receiving the first dose of study drug (or within 3 months for a trial
             with an investigational biologic).

         10. Disease-related surgical intervention within 1 month prior to the first dose of study
             drug.

         11. Use of supplements that are contraindicated in the opinion of investigator, including
             super-fortified foods and/or beverages that include coenzyme Q10, Vitamin C, Vitamin
             E, and/or idebenone, etc, unless receiving stable doses for a minimum of 30 days prior
             to enrollment. Changes to mitochondrial dietary supplements or their doses for 30 days
             prior to enrollment.

         12. Known hypersensitivity to ABI-009 (nab-sirolimus; ie, sirolimus and albumin), to any
             of its excipients, or to any known rapamycin derivative or known mTOR inhibitor.

         13. Patients with confirmed or suspected increased intracranial pressure, pseudotumor
             cerebri (PTC)/idiopathic intracranial hypertension, and/or papilledema.

         14. Any uncontrolled serious illness or psychiatric condition, medical condition, or other
             medical history, including abnormal laboratory test results which, in the opinion of
             the investigator, would be likely to interfere with the patient's participation in the
             study, or with the interpretation of the results of the study.

         15. Currently active malignancy (other than adequately treated non-melanoma skin cancers
             [ie, squamous cell and/or basal cell carcinoma], carcinoma in situ of the cervix, or
             other adequately treated carcinoma in situ) and/or ongoing treatment for malignancy
             are ineligible. Patients are not considered to have a currently active malignancy if
             they have completed therapy and are free of disease for ≥1 year.

         16. Recent infection requiring systemic anti-infective treatment that was completed ≤14
             days prior to enrollment.

         17. Confirmed or suspected immunodeficiency disorder(s), including but not limited to,
             common variable immune deficiency (CVID), complement deficiency, etc.

         18. Uncontrolled diabetes mellitus, as defined by HbA1c &gt;8%, despite adequate therapy.

         19. History of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.

         20. Use of strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) and/or
             p-glycoprotein (p-GP) within the 14 days prior to receiving the first dose of study
             drug. Additionally, use of any known CYP3A4 substrates with a narrow therapeutic
             window (eg, fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide,
             quinidine, terfenadine) within the 14 days prior to receiving the first dose of study
             drug. [All medications will be reviewed by the (Institutional) Investigational
             Pharmacy to ensure that strong inducers and/or inhibitors of CYP3A4 and/or p-GP, or
             CYP3A4 substrates with a narrow therapeutic window, have not been administered within
             14 days prior to the first dose of study drug; patients receiving anticonvulsant
             medications within the 14 days prior to receiving the first dose of study drug may be
             enrolled at the discretion of the investigator].

         21. Known human immunodeficiency virus (HIV), active hepatitis B or hepatitis C
             infection(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Berta Grigorian</last_name>
    <phone>8184168378</phone>
    <email>bgrigorian@aadibio.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leigh Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

